Rochester, Minnesota
Cancer biologic therapy trials in Rochester, MN
39 cancer biologic therapy studies are recruiting participants at sites in Rochester as of November 18, 2026, according to ClinicalTrials.gov. Cancer Biologic Trials can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Rochester at a glance
- 39 studies are recruiting at a site in Rochester.
- By phase: Phase 1 (7), Phase 1/2 (4), Phase 2 (13), Phase 2/3 (2), Phase 3 (13).
- By sponsor: university, hospital or other (19), industry (12), government (8).
- By research area: Lymphoma (17), Lung Cancer (9), Breast Cancer (7), Melanoma (3), Prostate Cancer (2), Pancreatic Cancer (1).
- Most recent update to one of these records: November 18, 2026.
Breast cancer studies recruiting in Rochester
Basic details from each study's public record (the 30 most recently updated of 39). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Phase 2
- All ages
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05564377 · updated
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06876714 · updated
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- BriaCell Therapeutics Corporation
- Study site
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic
- Registry record
- NCT06072612 · updated
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05812807 · updated
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04521764 · updated
Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Lung cancer studies recruiting in Rochester
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04267848 · updated
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic - Rochester ( Site 0073)
- Registry record
- NCT06312137 · updated
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- Mayo Clinic - Rochester ( Site 0148)
- Registry record
- NCT06170788 · updated
Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06918132 · updated
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06116682 · updated
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Phase 2/3
- Ages 18 and older
- All sexes
- Sponsor
- SWOG Cancer Research Network
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06616584 · updated
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
- Phase 1/2
- Ages 18 and older
- All sexes
- Sponsor
- BioNTech SE
- Study site
- Mayo Clinic-Rochester
- Registry record
- NCT06892548 · updated
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- NRG Oncology
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05624996 · updated
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- Phase 1
- Ages 18 and older
- All sexes
- Sponsor
- Xencor, Inc.
- Study site
- Xencor Investigative Site
- Registry record
- NCT05433142 · updated
Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Prostate cancer studies recruiting in Rochester
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT03866382 · updated
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- Phase 1
- Ages 18 to 100
- Male participants
- Sponsor
- Janux Therapeutics
- Study site
- Mayo Clinic
- Registry record
- NCT05519449 · updated
Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Melanoma studies recruiting in Rochester
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05136196 · updated
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Immatics US, Inc.
- Study site
- Mayo Clinic
- Registry record
- NCT06743126 · updated
Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Rochester, MN on ClinicalTrials.gov.
Lymphoma studies recruiting in Rochester
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06337318 · updated
Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT04840602 · updated
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Phase 3
- Ages 5 to 60
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT05675410 · updated
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Phase 3
- Ages 18 and older
- All sexes
- Sponsor
- Lyell Immunopharma, Inc.
- Study site
- Mayo Clinic Rochester
- Registry record
- NCT07188558 · updated
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Phase 3
- Ages 18 to 39
- All sexes
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT03150693 · updated
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Phase 2
- From 366 days, up to 46 years
- All sexes
- Sponsor
- National Cancer Institute (NCI)
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06124157 · updated
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT03516617 · updated
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- Phase 1/2
- Ages 13 to 90
- All sexes
- Sponsor
- Vironexis Biotherapeutics Inc.
- Study site
- Mayo Clinic, Clinical Trials Referral Office
- Registry record
- NCT06533579 · updated
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT06834373 · updated
Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT03418038 · updated
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Phase 3
- From 365 days, up to 25 years
- All sexes
- Sponsor
- Children's Oncology Group
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT03959085 · updated
Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Rochester, MN on ClinicalTrials.gov.
Pancreatic cancer studies recruiting in Rochester
BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
- Phase 2
- Ages 18 and older
- All sexes
- Sponsor
- Mayo Clinic
- Study site
- Mayo Clinic in Rochester
- Registry record
- NCT07226856 · updated
Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Rochester, MN on ClinicalTrials.gov.
Ask about studies near Rochester
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Minnesota
All Minnesota locations
78 studies recruiting across 47 cities.
Minneapolis
48 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that test a biologic, such as a vaccine, an antibody, or a cell or gene therapy, as each study is coded in the registry.
Cancer Biologic Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections